Person:
ŞİMŞEK, MELİH

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
MELİH
Last Name
ŞİMŞEK
Name
Email Address
Birth Date

Search Results

Now showing 1 - 4 of 4
  • PublicationMetadata only
    Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years- Experience
    (2016-02-01T00:00:00Z) Turkeli, Mehmet; Simsek, MELİH; Aldemir, Mehmet Naci; Yildirim, Nilgun; ÇANKAYA, Erdem; ERDEMCİ, Burak; BİLİCİ, Mehmet; TEKİN, Salim Başol; Arslan, Sukru; KORKUT, Ercan; ŞİMŞEK, MELİH
    Objective: Our aim is to evaluate the frequency and characteristics of cancer in the population of patients with solid organ transplant who are under immunosuppressive medication. In this study we aimed to emphasize the importance of early diagnosis of cancer in solid organ transplant recipients. An aging population began to receive solid organ transplantation and survival times prolonged. But this had a cost and new problems came forward. Especially de novo cancers because of immunosuppressive therapy took notice. Risk of malignancy increases after organ transplantation and cancer incidence was about 2.3-3.1% in these patients including skin cancer, lung cancer, malign lymphoma, cervix cancer, kaposi sarcoma, and hepatobiliary cancer.
  • PublicationMetadata only
    Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers
    (2019-06-01T00:00:00Z) Yildirim, Nilgun; Simsek, MELİH; Aldemir, Mehmet Naci; BİLİCİ, Mehmet; TEKİN, Salim Başol; ŞİMŞEK, MELİH
    Objective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC).
  • PublicationMetadata only
    Immunological Agents Used in Cancer Treatment
    (2019-02-01T00:00:00Z) Simsek, MELİH; TEKİN, Salim Başol; BİLİCİ, Mehmet; ŞİMŞEK, MELİH
    Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI. CTLA-4 is a brake mechanism in immune response. Ipilimumab and tremelimumab are antibodies against CTLA-4. PD-1 is another important immune checkpoint co-inhibitor receptor that is expressed by activated T cells in the peripheral tissue. As a result of blockage of the PD-1/PD-L1 pathway, local tumor-specific immune response augments, and long-term tumor control can be achieved. In recent years, ICI are approved for the treatment of various malignities. They may be responsible for specific toxicities called immune-related adverse events (irAEs). irAEs are a consequence infiltration of normal tissues by activated T lymphocytes that are responsible for autoimmunity. Corticosteroids and anti-tumor necrosis factor agents, such as infliximab and mycophenolate mofetil, are effective in the treatment of irAEs. Immune checkpoint inhibition with monoclonal antibodies against CTLA-4 and/or PD-1/PD-L1 by single agent or combination treatments became a new option in various solid tumors. However, ICI have unique adverse events, and these adverse events should be considered in any new onset clinical situation and should be managed properly. Future prospective randomized clinical trials will clarify recent questions.
  • PublicationMetadata only
    The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib
    (2021-08-01T00:00:00Z) YILMAZ, Ali; ŞİMŞEK, MELİH; HANNARİCİ, Zekeriya; Buyukbayram, Mehmet E.; BİLİCİ, Mehmet; Tekin, Salim B.; ŞİMŞEK, MELİH
    Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.